TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06639607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus booster
Description: Td 5 flocculation units, Lf

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus booster
Description: Td 5 flocculation units, Lf

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus booster
Description: Td 5 flocculation units, Lf

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study: NCT05732766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Study: NCT06270979

Intervention type: DEVICE
Intervention: ISHA
Description: Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).

Intervention type: DEVICE
Intervention: ISHA
Description: Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).
Study: NCT05405647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
Study: NCT05481866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Description: The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oropharyngeal administration of sterile water
Description: The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
Study: NCT05999825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE Vaccine
Description: 30 μg Sm-p80 + 5 μg GLA-SE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sterile Normal Saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Schistosoma mansoni infection
Description: 20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Schistosoma mansoni infection
Description: 20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
Study: NCT04676048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC618
Description: ASC618 will be given as a single IV infusion
Study: NCT05116670

Intervention type: OTHER
Description: this is an observation study, no intervention is needed

Intervention type: OTHER
Description: this is an observation study, no intervention is needed
Study: NCT04462406

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ipilimumab
Description: Given IV
Study: NCT05618873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter device
Description: The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positive expiratory pressure mask
Description: The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times.
Study: NCT05708001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography (hdEEG)
Description: EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline, after 4 weeks and 12 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
Study: NCT05782829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tyrosine supplementation
Description: L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo supplementation before surgery for inguinal hernia under general anaesthesia
Study: NCT06272344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation at 6 months
Study: NCT04462406

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo active surveillance

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab
Description: Given IV
Study: NCT06370416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
Study: NCT00000815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuvax
Description: Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R-II
Description: Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R-II
Description: Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
Study: NCT05675137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile-based
Description: Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based
Description: Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
Study: NCT04182867

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Dietary modification (provision of diet).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary modification (provision of diet).
Study: NCT06435702

Intervention type: DRUG
Intervention: Darolutamide in addition to androgen deprivation therapy
Description: Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration

Intervention type: DRUG
Intervention: androgen deprivation therapy only
Description: The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
Study: NCT05772637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated cystometries with bladder sensations assessment
Description: A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
Study: NCT06446557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment adaptation guided by ctDNA variation
Description: after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard management
Description: At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
Study: NCT05438667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T therapy
Description: 1.Preprocessing strategy：~1. Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed .
Study: NCT05286606

Intervention type: BEHAVIORAL
Intervention: Exercise and Social Groups
Description: Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support.
Study: NCT05163288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-L-Leucine
Description: N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Sachet
Study: NCT05840939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama
Description: Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragm breathing exercise
Description: Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
Study: NCT05032820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and bb2121
Description: Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
Study: NCT06199245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique experimental group
Description: Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
Study: NCT04865965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Bout of Exercise
Description: Exercising for 60 minutes at 55-60% of VO₂ peak
Study: NCT05965674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Plane Block
Description: The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
Study: NCT05187832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND019 PO QD
Description: AND019 administrated as oral capsule once per day for 28 days for each cycle
Study: NCT04947527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test varnish
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
Study: NCT05320575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
Study: NCT04230447

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04193930

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Oral tablet letrozole 2,5 mg/twice daily for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Menotropins
Description: 150 IU of highly purified menotropins intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Menotropins
Description: 150 IU of highly purified menotropins intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: recombinant Follicular stimulating hormone
Description: recombinant Follicular stimulating hormone 300- 400 IU
Study: NCT04965740

Intervention type: DRUG
Intervention: Cannabis
Description: Recreational Cannabis

Intervention type: DRUG
Intervention: Cannabis
Description: Recreational Cannabis
Study: NCT05729009

Intervention type: DIAGNOSTIC_TEST
Intervention: skin microvascular reactivity
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
Study: NCT05927883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenously Adapted Cognitive Behavioral Therapy
Description: IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indigenously Adapted Cognitive Behavioral Therapy
Description: IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
Study: NCT06076629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16#) group
Description: The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Moderate temperature (22#) group
Description: The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
Study: NCT05533892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton
Description: Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg intravenously every 3 weeks